European MedTech venture capital has matured substantially over the past decade, but it still writes smaller cheques than the US at equivalent stages and concentrates around a handful of specialist funds in the UK, France, Germany, Switzerland, and the Nordics. In 2026, a European MedTech founder should expect a pre-seed of several hundred thousand euros, a seed round roughly in the low single-digit millions, a Series A tied to a concrete regulatory or clinical milestone, and a Series B that funds commercial launch and reimbursement work. The deal will be slower than SaaS, the diligence will be deeper, and the term sheet will contain provisions that do not exist in generalist tech rounds. Founders who understand this landscape before they start raising will close better terms than founders who learn it during negotiation.

By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.

TL;DR

  • European MedTech VC is real, professional, and specialist-driven — but round sizes at seed and Series A remain noticeably smaller than US equivalents for similar companies.
  • The investor landscape in 2026 concentrates around health-focused funds in London, Paris, Munich, Zurich, Stockholm, and Copenhagen, plus the EIC Fund and a growing set of corporate venture arms from strategic acquirers.
  • MedTech rounds are paced by regulatory milestones, not by growth metrics. A European Series A is almost always tied to CE mark proximity, clinical evidence, and a credible reimbursement pathway.
  • Term sheets in European MedTech rounds routinely include exclusivity clauses, liquidation preferences, and anti-dilution mechanics that a SaaS founder may not have seen before. Some of these are reasonable. Some are company-killers if signed in a hurry.
  • The regulatory deck slide is the single highest-leverage page in a European MedTech pitch deck. Get it right and specialist investors engage immediately; get it wrong and the process dies silently.

Why this matters for your startup

If you are raising for a MedTech company in Europe in 2026, you are raising into a market that has grown up considerably since the MDR (Regulation (EU) 2017/745) became applicable in May 2021. A generation of European health-tech funds has now been through one or more full cycles of post-MDR portfolio experience. They know what the Notified Body bottleneck looks like. They have seen companies miss their CE mark dates. They have written down investments that failed reimbursement. They have also seen CE-marked, reimbursement-backed European MedTech companies exit to US strategics at real multiples.

This maturity cuts both ways. On the one hand, specialist European MedTech investors in 2026 are easier to talk to than they were five years ago — they understand the domain and they will not panic at the first mention of a Notified Body delay. On the other hand, they are harder to fool. A pitch deck that glosses over classification, clinical strategy, or reimbursement will not survive their first diligence pass. The bar has gone up.

This post is a ground-level map of the European MedTech VC landscape as it stands in 2026, and a practical guide for what a founder should expect at each stage. It is the sibling post to the funding pillar and why MedTech needs more capital than SaaS. Read those first if you have not.

European MedTech VC versus the US reality

Start with the honest comparison. American MedTech venture capital writes larger cheques earlier. A US seed round for a comparable device company is often double or triple what a European MedTech startup would raise at the same stage, and the US Series A gap is larger still. This is not a criticism of European funds — it is a structural feature of the two markets. US funds sit inside a larger, deeper LP base and face a domestic exit market with bigger public comparables.

What this means in practice is that European MedTech founders should expect to run leaner for longer and to reach more regulatory and clinical progress per euro raised than a US peer would need to. It also means that the European cap table is typically less diluted at the same stage, because the rounds are smaller — the trade is runway for ownership.

The stage thesis also differs. US MedTech VC is more comfortable funding pre-clinical and early-prototype work on venture terms. European MedTech VC tends to prefer entering once the regulatory pathway is clearer and the team has absorbed some of the early risk through grants, angels, or corporate partnerships. This is changing — specialist European funds are moving earlier — but the pattern still holds in 2026.

Round sizes vary widely by country, subsector, and fund. What we can say honestly is that the median European MedTech seed round is smaller than the median US one, and the gap widens at Series A. A founder who benchmarks their European raise against US numbers will either be disappointed or will set expectations that cannot be met. Benchmark against European comparables.

The stages: pre-seed, seed, Series A, growth

Pre-seed

European MedTech pre-seed rounds in 2026 are typically assembled from a mix of non-dilutive grants, angel cheques, and occasionally a small institutional lead. The purpose is to get the company from idea to first prototype, first intended-purpose definition, and first conversations with a Notified Body or clinical partner.

Expect investor questions at this stage to focus on team composition, the credibility of the regulatory plan, and whether the intended purpose will produce a defensible classification. A pre-seed pitch that cannot clearly answer "what class will this device be and why" is not yet ready for institutional money.

For European founders, non-dilutive funding — FFG, AWS, and BASIS in Austria; Bpifrance in France; Innovate UK in the UK; Vinnova in Sweden; the EIC Accelerator at the EU level — should be exhausted or at least in progress before pre-seed equity is taken. The dilution math is unforgiving if you skip this step. We cover this in more detail in the funding pillar post.

Seed

A European MedTech seed round is the first proper institutional round. It is typically led by a specialist health-tech fund and pulled together with angel co-investors and sometimes a strategic corporate. The purpose is to take the company from prototype to a credible pre-submission conversation with a Notified Body, to generate early clinical or usability evidence, and to begin building the technical file under MDR Article 10.

Investor expectations at this stage become concrete. The seed-stage diligence will include a regulatory pathway review, a classification rationale check, a review of the clinical evaluation strategy under MDR Article 61, and usually a team assessment to see whether the company has someone who can own the PRRC and QMS responsibilities. If your team does not yet have regulatory depth, expect the term sheet to either require a hire or to include milestone-based tranching.

Series A

Series A is where European MedTech rounds start to look, at least superficially, like their US counterparts. The round is larger, the diligence is deeper, the board seat is formal, and the milestones are sharp. In European MedTech in 2026, Series A is almost always tied to a specific regulatory or clinical milestone: CE mark approaching, pivotal clinical evidence complete, first commercial LOIs signed, reimbursement pathway identified.

Investors at Series A will ask hard questions about the post-market surveillance plan under MDR Article 83, about the PMS system's readiness for ongoing compliance, and about the operational maturity of the QMS under EN ISO 13485:2016+A11:2021. They will ask about reimbursement separately from CE mark — if you are treating reimbursement as a post-launch problem, the meeting will end.

Growth (Series B and beyond)

Growth rounds fund commercial ramp, geographic expansion within the EU, second-indication development, and the build-out of the post-market and vigilance functions that an in-market device must sustain. Investor appetite for European MedTech growth rounds in 2026 is thinner than at earlier stages — many European MedTech companies raise their growth round from US funds or from strategic corporates, and some choose an earlier exit instead of a full growth round. This shapes the exit conversation that a European Series A investor will want to have with you.

Regulatory milestones as valuation drivers

Here is the most important frame for a European MedTech founder to internalise: in this industry, valuation does not step up on MRR. It steps up on regulatory milestones. The moments that change the valuation curve are, in rough order:

  • Classification rationale agreed and defensible.
  • Notified Body selected and pre-submission engagement live.
  • Clinical evaluation plan reviewed and accepted.
  • Technical file submitted.
  • CE mark issued.
  • First reimbursement decisions in key markets.
  • First commercial revenue and PMS data.

Between these milestones, valuation is essentially flat and occasionally negative as runway burns. This is the opposite of the SaaS curve, where continuous growth drives continuous revaluation. In MedTech, valuation is staircase-shaped, not sloped. This has real implications for fundraising: time your rounds to land shortly after a milestone, not shortly before one. A round raised just before CE mark carries the risk of the CE mark delay; a round raised just after captures the step-up.

Tibor has seen this pattern play out across dozens of companies: the teams that manage their milestone calendar against their fundraising calendar raise at materially better terms than teams that raise whenever the cash is running low.

Due diligence patterns

European MedTech VC diligence in 2026 is deeper than SaaS diligence at the same stage. Expect the process to include at least:

  • Regulatory diligence. A specialist regulatory affairs advisor — sometimes internal to the fund, sometimes external — will review the classification, intended purpose, clinical evaluation approach, and Notified Body plan. They will look for gaps, optimistic assumptions, and missing documentation.
  • Clinical diligence. A clinical advisor will review the clinical evaluation strategy, the adequacy of the literature review, any investigator-initiated data, and the plan for pivotal evidence.
  • Technical diligence. A product-and-engineering review looking at software architecture, cybersecurity posture, and the state of the technical file.
  • QMS diligence. Sometimes a light review of the QMS maturity, sometimes a serious one — especially at Series A.
  • Reimbursement diligence. Market-by-market review of payer pathways in the key target geographies. This is the area that most founders are least prepared for and that most European MedTech funds now scrutinise closely.
  • Commercial diligence. Reference calls with clinical champions, KOLs, early customers, and health system contacts.

Expect the process to take longer than a SaaS diligence — eight to sixteen weeks is normal for Series A. Rushing the process is a warning sign on both sides. A fund that wants to close in two weeks is either not doing the work or is exploiting a pressured founder. A founder who wants to close in two weeks is likely out of money, which weakens every negotiating position they have.

Term sheet traps — exclusivity, liquidation preferences, dilution

There are provisions in European MedTech term sheets in 2026 that are worth reading slowly, ideally with counsel who has closed MedTech rounds specifically.

Exclusivity clauses. Most term sheets require a period of exclusivity during which the company cannot negotiate with other investors. Reasonable exclusivity is short — a few weeks — and is granted only once diligence is meaningfully underway. Unreasonable exclusivity is a multi-month block, granted early, with no defined exit. We have watched a specific pattern play out: a founder enters exclusivity with an investor who seems close to closing, the closing slips, the terms soften at the last minute, and by the time the deal collapses the company has burned through runway it cannot replace because it could not talk to anyone else. The exclusivity clause felt reasonable at signing. It was catastrophic in execution.

The discipline is to keep exclusivity periods short, to tie them to specific diligence milestones, and to walk away from any investor who demands long or open-ended exclusivity before real diligence has started. This is a discipline thing, not a trust thing — trustworthy investors will accept reasonable exclusivity because reasonable exclusivity is all they need.

Liquidation preferences. A 1x non-participating preference is standard and reasonable in most European MedTech rounds. A 2x or participating preference is an aggressive structure that compounds across rounds and can strand common stock in a mediocre exit. Multiple-round participating preferences are particularly dangerous because by the time the company is ready to exit, the founder and employee equity may be effectively worthless even at a seemingly decent valuation. Read the preference stack on every round. Model the exit waterfall. If you cannot explain to a new hire what their options will be worth in a EUR 50 million exit, the cap table is too complex.

Anti-dilution mechanics. Full-ratchet anti-dilution is rare in European MedTech rounds, but broad-based weighted-average anti-dilution is common and generally reasonable. The risk is stacking anti-dilution across rounds in a way that quietly redistributes ownership during down rounds or flat extensions — which, in MedTech, are not rare events given the regulatory delay profile.

Milestone tranching. European MedTech Series A term sheets sometimes release capital in tranches tied to regulatory or clinical milestones. This is reasonable in principle but becomes a trap if the milestones are defined in a way that gives the investor unilateral discretion to withhold tranches. The milestones should be objective — CE mark issued, first patient enrolled, first commercial contract signed — not subjective.

Board composition and control. At Series A the board typically expands to include the lead investor. The question to ask is how board decisions interact with regulatory and clinical decisions. An investor board majority that can override the CEO on pivot decisions is a structural risk for a MedTech company whose regulatory path depends on stable intended purpose. Keep these decisions founder-protected where possible.

How to prepare the regulatory deck slide

For a European MedTech pitch deck in 2026, the single highest-leverage slide is the one that summarises the regulatory plan. It belongs near the front of the deck, right after the problem and product slides, and before the market and traction slides. It tells the specialist investor whether you understand the domain.

What the slide should contain:

  • Classification. The class you believe the device falls into, with the specific MDR classification rule cited. If there is borderline ambiguity, say so and explain your defence.
  • Intended purpose. One clear sentence. Not marketing language. Not aspirational. The actual intended purpose as it will appear on the label and in the technical file.
  • Conformity assessment route. Which Annex route you will use, whether a Notified Body is involved, and which one you are engaging.
  • Clinical evaluation approach. Whether you are relying on literature review, equivalence, or your own clinical investigation under MDR Article 61.
  • Timeline to CE mark. An honest, milestone-based timeline — not a wish.
  • Reimbursement pathway. One line per target country, naming the mechanism.
  • Team gaps. What regulatory and clinical hires are planned with the round proceeds.

A founder who can deliver this slide in ninety seconds, with numbers and without hedging, moves specialist investors from polite interest to real engagement. A founder who cannot — regardless of how good the product is — will be filed under "come back when regulatory is clearer."

The Subtract to Ship angle — raise for milestones, not for months

The Subtract to Ship framework applied to European MedTech fundraising says this: raise enough to reach the next milestone cleanly, plus a buffer for the inevitable regulatory delay. Do not raise to fund a fixed number of months of burn. Do not raise to fund every feature on the roadmap. Raise against the specific regulatory or clinical step-up that will unlock the next round at a better valuation.

The discipline is to subtract everything from the round size that does not directly buy milestone progress. The vanity hires, the early sales team, the conference booth, the second product line — if they do not buy milestone progress, they dilute the company without adding valuation support. Keep the round tight enough to be raisable, generous enough to absorb the regulatory delay that will happen, and targeted at one milestone, not three.

This is not about raising as little as possible. It is about raising the right amount for the right purpose. Tibor's phrasing applies here as much as anywhere in the book: more money thrown at compliance theatre is still compliance theatre.

Reality Check — Where do you stand?

  1. Have you benchmarked your target round size against European MedTech comparables, not US ones?
  2. Do you know which specific European specialist funds are actively investing at your stage in your subsector, and have you identified why each of them might say yes or no?
  3. Can you deliver your regulatory plan slide in ninety seconds, cold, without hedging?
  4. Is your target close date tied to a specific upcoming milestone that will justify the next step-up?
  5. Have you modelled your exit waterfall under realistic valuation scenarios — and have you checked that your employee option pool is still meaningful after the preference stack is paid?
  6. Have you read every exclusivity clause in your current term sheet draft, checked its duration, and confirmed there is an objective end date?
  7. Do you have term-sheet-specialist counsel with European MedTech deal experience — not just generalist startup counsel?
  8. Is your current runway long enough that you can walk away from a bad term sheet without killing the company?

Frequently Asked Questions

Is European MedTech VC really behind US MedTech VC in 2026? European MedTech VC is smaller in cheque size at comparable stages but not behind in sophistication. Specialist European funds in 2026 understand the MDR, the Notified Body bottleneck, and the reimbursement pathway in deep detail. The gap is in absolute capital deployed per round, not in the quality of the diligence or the strategic value an investor brings.

What is a typical Series A size for a European MedTech startup in 2026? It varies widely by subsector, country, and the specific regulatory stage. What is consistent is the pattern: the round is tied to a concrete regulatory or clinical milestone, and the amount reflects the capital needed to reach and extend past that milestone. Benchmark against European comparables in your specific subsector rather than against a general "average."

Should I take US money instead of European money? If you can. US rounds are typically larger at the same stage, but US investors may have different expectations about commercial scale and timing. US money also often comes with pressure to enter the US market via the FDA, which is a separate multi-year project. Many European MedTech companies raise early rounds locally and bring in US capital at Series B or C when the US commercial opportunity becomes concrete.

How long does a European MedTech Series A process take? Eight to sixteen weeks is normal for Series A, from first meeting to signed term sheet, with a further few weeks to closing. Seed rounds are faster. Rushing either process is usually a warning sign.

What is the single most dangerous clause in a European MedTech term sheet? Long, open-ended exclusivity combined with no objective end date. It hands the counter-party control of your runway while stripping your ability to run a competitive process. Every other problematic clause — preferences, anti-dilution, milestone tranching — can be negotiated once you have options. Exclusivity takes the options away.

How important is specialist MedTech counsel? Critical. Generalist startup lawyers will draft generalist startup term sheets. MedTech-specialist counsel will recognise the exclusivity traps, the clinical-milestone tranching pitfalls, and the board-control risks that are specific to regulated companies. The cost of specialist counsel is small relative to the cost of a bad clause.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Article 10 (manufacturer obligations), Article 61 (clinical evaluation), Article 83 (post-market surveillance system). Official Journal L 117, 5.5.2017.
  2. EN ISO 13485:2016 + A11:2021 — Medical devices — Quality management systems — Requirements for regulatory purposes.
  3. European Innovation Council (EIC) Fund, program information. https://eic.ec.europa.eu — verify current investment thesis and cheque sizes directly with the fund before relying on specific figures.
  4. National non-dilutive funding agencies referenced in this post (FFG, AWS, BASIS, Bpifrance, Innovate UK, Vinnova) — verify current program terms and eligibility criteria directly with each agency before relying on specific figures.

This post is part of the Funding, Business Models & Reimbursement series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. When the specifics of your European MedTech round — the classification edge case, the exclusivity clause, the reimbursement question an investor just asked — move beyond what a blog post can cover, a sparring partner who has sat on both sides of a term sheet is the shortest path to a round you will still be happy with three years from now.